Predictors of outcome in 216 subjects with ARDS treated with inhaled epoprostenol.

摘要: BACKGROUND: ARDS is an important cause of respiratory failure and continues to be associated with a high mortality rate. Numerous therapeutic interventions have been employed improve patient outcomes, including inhaled epoprostenol. METHODS: We examined subjects treated compared hospital survivors nonsurvivors identify predictors mortality. RESULTS: Among the cohort (n = 216), there were 80 (37%) 136 (63%) nonsurvivors. Logistic regression revealed 5 variables mortality: trauma as etiology for (adjusted odds ratio [AOR] 0.09, 95% CI 0.04–0.22, P .006), presence both pulmonary nonpulmonary sources sepsis (AOR 3.06, 1.98–4.74, .01), international normalized > 1.5 3.15, 2.19–4.54, .002), body mass index (1-unit increments, AOR 0.95, 0.936–0.965, .001), incremental change in PaO2/FIO2 during first 24 h treatment epoprostenol 0.99, 0.988–0.994, .002). An analysis 90-d identified same predictors, addition cumulative fluid balance 4 L also being independent predictor 2.36, 1.66–3.37, .02). CONCLUSIONS: Although use remains challenge, we able this patients. These could design future trials ARDS.